TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake
Brief Summary: The purpose of the study is to find a good therapy for patients who need to be treated for high cholesterol and who have difficulty tolerating other statins (such as pravastatin, simvastatin, lovastatin, atorvastatin, rosuvastatin) due to muscle pain.


Options:
A: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
B: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg
C: Arm Label: LZ group; Type: EXPERIMENTAL; Interventions: Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe] | Arm Label: L group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lipitor (Atorvastatin) monotherapy | Intervention Type: DRUG; Name: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Assigned to Arm(s): LZ group | Intervention Type: DRUG; Name: Lipitor (Atorvastatin) monotherapy; Assigned to Arm(s): L group
D: Arm Label: Atorvastatin + Evacetrapib; Type: EXPERIMENTAL; Interventions: Drug: Evacetrapib, Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin 80 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Evacetrapib; Assigned to Arm(s): Atorvastatin + Evacetrapib | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin + Evacetrapib, Atorvastatin + Ezetimibe, Atorvastatin 40 mg, Atorvastatin 80 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Atorvastatin + Ezetimibe | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atorvastatin + Evacetrapib, Atorvastatin + Ezetimibe, Atorvastatin 40 mg, Atorvastatin 80 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake
Brief Summary: The purpose of the study is to find a good therapy for patients who need to be treated for high cholesterol and who have difficulty tolerating other statins (such as pravastatin, simvastatin, lovastatin, atorvastatin, rosuvastatin) due to muscle pain.


Options:
A: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
B: Arm Label: Fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluvastatin | Arm Label: Fluvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin plus ezetimibe | Intervention Type: DRUG; Name: fluvastatin; Assigned to Arm(s): Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin plus ezetimibe; Assigned to Arm(s): Fluvastatin + Ezetimibe
C: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Chest Physiotherapy With Forced Expiratory Technique for Acute Bronchiolitis in Toddlers
Brief Summary: The purpose of this study is to determine whether chest physiotherapy with forced expiratory technique reduces delay of healing in acute bronchiolitis of children between 15 days and 24 months of age.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy with Forced Expiratory Technique | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasopharyngeal Aspiration | Intervention Type: PROCEDURE; Name: Chest Physiotherapy with Forced Expiratory Technique; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Nasopharyngeal Aspiration; Assigned to Arm(s): B
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Intervention
C: Arm Label: Rhinopharyngeal clearance + 0.9% saline; Type: EXPERIMENTAL; Interventions: Procedure: Rhinopharyngeal clearance, Other: 0.9% saline | Arm Label: Aspiration + 0.9% saline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Aspiration, Other: 0.9% saline | Intervention Type: PROCEDURE; Name: Rhinopharyngeal clearance; Assigned to Arm(s): Rhinopharyngeal clearance + 0.9% saline | Intervention Type: PROCEDURE; Name: Aspiration; Assigned to Arm(s): Aspiration + 0.9% saline | Intervention Type: OTHER; Name: 0.9% saline; Assigned to Arm(s): Aspiration + 0.9% saline, Rhinopharyngeal clearance + 0.9% saline
D: Arm Label: 1- Conventional Chest Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy - Conventional | Arm Label: 2- Chest physiotherapy- Actual techniques; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy - actual techniques | Arm Label: 3- Airway Suction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3-Airway suction | Intervention Type: PROCEDURE; Name: Chest physiotherapy - Conventional; Assigned to Arm(s): 1- Conventional Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy - actual techniques; Assigned to Arm(s): 2- Chest physiotherapy- Actual techniques | Intervention Type: PROCEDURE; Name: 3-Airway suction; Assigned to Arm(s): 3- Airway Suction

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
Brief Summary: The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil- Blopress®) and a calcium channel blocker (amlodipine besilate- Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.


Options:
A: Intervention Type: DRUG; Name: Candesartan cilexetil; Assigned to Arm(s): N/A
B: Arm Label: felodipine group, active, pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Felodipine | Arm Label: placebo, no treatment, pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Felodipine; Assigned to Arm(s): felodipine group, active, pill | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo, no treatment, pill
C: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
D: Arm Label: Benazepril/amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Arm Label: Benazepril/hydrochlorothiazide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Intervention Type: DRUG; Name: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/amlodipine | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2; Assigned to Arm(s): Benazepril/hydrochlorothiazide | Intervention Type: DRUG; Name: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Assigned to Arm(s): Benazepril/hydrochlorothiazide

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
Brief Summary: The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil- Blopress®) and a calcium channel blocker (amlodipine besilate- Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.


Options:
A: Arm Label: Multi-PAP intervention; Type: EXPERIMENTAL; Interventions: Other: Multi-PAP, Other: Usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Multi-PAP; Assigned to Arm(s): Multi-PAP intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Multi-PAP intervention, Usual care
B: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
C: Intervention Type: BEHAVIORAL; Name: Self-management of chronic illness; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Candesartan cilexetil; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial
Brief Summary: The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for revascularization procedures in patients with chronic kidney disease (CKD). It also aimed to assess whether lowering LDL cholesterol reduced the rate of loss of renal function in people with CKD who had not commenced dialysis treatment.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Diet+pravastatin; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Simvastatin 20mg plus Ezetimibe 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin 20 mg, Drug: Ezetimibe 10mg | Arm Label: Simvastatin 20mg; Type: OTHER; Interventions: Drug: Simvastatin 20 mg | Intervention Type: DRUG; Name: Simvastatin 20 mg; Assigned to Arm(s): Simvastatin 20mg, Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Ezetimibe 10mg; Assigned to Arm(s): Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Statin (simvastatin); Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial
Brief Summary: The chief aim of SHARP was to determine whether lowering blood LDL cholesterol with simvastatin (20mg) plus ezetimibe (10mg) daily could safely reduce the risk of coronary heart disease, non-hemorrhagic stroke and the need for revascularization procedures in patients with chronic kidney disease (CKD). It also aimed to assess whether lowering LDL cholesterol reduced the rate of loss of renal function in people with CKD who had not commenced dialysis treatment.


Options:
A: Arm Label: SANDS Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SANDS Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: FDA approved drugs to treat blood pressure and cholesterol | Intervention Type: DRUG; Name: FDA approved drugs to treat blood pressure and cholesterol; Assigned to Arm(s): SANDS Intervention Group
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Simvastatin 20mg plus Ezetimibe 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin 20 mg, Drug: Ezetimibe 10mg | Arm Label: Simvastatin 20mg; Type: OTHER; Interventions: Drug: Simvastatin 20 mg | Intervention Type: DRUG; Name: Simvastatin 20 mg; Assigned to Arm(s): Simvastatin 20mg, Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Ezetimibe 10mg; Assigned to Arm(s): Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: EZ/Simva; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (plus simvastatin) | Arm Label: Placebo/Simva; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (plus simvastatin) | Intervention Type: DRUG; Name: ezetimibe (plus simvastatin); Assigned to Arm(s): EZ/Simva | Intervention Type: DRUG; Name: placebo (plus simvastatin); Assigned to Arm(s): Placebo/Simva
D: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Measuring Reading Rehabilitation Outcomes
Brief Summary: The purpose of this study is to measure the effectiveness of a newly-designed oculomotor training program for patients with age-related macular degeneration.


Options:
A: Arm Label: Visual Reconstitution Therapy; Type: EXPERIMENTAL; Interventions: Other: Visual Reconstitutions Therapy | Arm Label: Saccadic Eye Movement Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Saccadic Eye Movement Training | Intervention Type: OTHER; Name: Visual Reconstitutions Therapy; Assigned to Arm(s): Visual Reconstitution Therapy | Intervention Type: OTHER; Name: Saccadic Eye Movement Training; Assigned to Arm(s): Saccadic Eye Movement Training
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Low Vision Intervention - Outpatient Training Program | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Vision Intervention - Outpatient Training Program; Assigned to Arm(s): Arm 1
C: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser
D: Intervention Type: PROCEDURE; Name: Eccentric Viewing Training for Reading; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease
Brief Summary: The purpose of this study is to evaluate whether the addition of warfarin (a blood-thinning medication) to an antiplatelet therapy like aspirin is better than antiplatelet therapy alone (i.e. usual treatment) for the prevention of leg surgery, heart attacks, stroke and death in people with peripheral vascular disease.


Options:
A: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4
B: Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia
Brief Summary: The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.


Options:
A: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arginine; Assigned to Arm(s): High Dose, Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: L-Arginine Hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: L-Arginine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline | Intervention Type: DRUG; Name: L-Arginine Hydrochloride; Assigned to Arm(s): L-Arginine Hydrochloride | Intervention Type: OTHER; Name: Normal saline; Assigned to Arm(s): Placebo
C: Arm Label: Dose Level 1; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic Acid | Arm Label: Dose Level 2; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic Acid | Arm Label: Dose Level 3; Type: EXPERIMENTAL; Interventions: Drug: Docosahexaenoic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Docosahexaenoic Acid; Assigned to Arm(s): Dose Level 1, Dose Level 2, Dose Level 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: investigational product; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): investigational product | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D